Historical Valuation
Guardant Health Inc (GH) is now in the Fair zone, suggesting that its current forward PS ratio of 11.32 is considered Fairly compared with the five-year average of -19.85. The fair price of Guardant Health Inc (GH) is between 15.75 to 180.38 according to relative valuation methord.
Relative Value
Fair Zone
15.75-180.38
Current Price：108.74
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Guardant Health Inc (GH) has a current Price-to-Book (P/B) ratio of -35.88. Compared to its 3-year average P/B ratio of -242.26 , the current P/B ratio is approximately -85.19% higher. Relative to its 5-year average P/B ratio of -137.92, the current P/B ratio is about -73.99% higher. Guardant Health Inc (GH) has a Forward Free Cash Flow (FCF) yield of approximately -2.00%. Compared to its 3-year average FCF yield of -8.92%, the current FCF yield is approximately -77.56% lower. Relative to its 5-year average FCF yield of -7.01% , the current FCF yield is about -71.46% lower.
P/B
Median3y
-242.26
Median5y
-137.92
FCF Yield
Median3y
-8.92
Median5y
-7.01
Competitors Valuation Multiple
AI Analysis for GH
The average P/S ratio for GH competitors is 2.95, providing a benchmark for relative valuation. Guardant Health Inc Corp (GH.O) exhibits a P/S ratio of 11.32, which is 283.9% above the industry average. Given its robust revenue growth of 38.50%, this premium appears sustainable.
Performance Decomposition
AI Analysis for GH
1Y
3Y
5Y
Market capitalization of GH increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GH in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GH currently overvalued or undervalued?
Guardant Health Inc (GH) is now in the Fair zone, suggesting that its current forward PS ratio of 11.32 is considered Fairly compared with the five-year average of -19.85. The fair price of Guardant Health Inc (GH) is between 15.75 to 180.38 according to relative valuation methord.
What is Guardant Health Inc (GH) fair value?
GH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Guardant Health Inc (GH) is between 15.75 to 180.38 according to relative valuation methord.
How does GH's valuation metrics compare to the industry average?
The average P/S ratio for GH's competitors is 2.95, providing a benchmark for relative valuation. Guardant Health Inc Corp (GH) exhibits a P/S ratio of 11.32, which is 283.90% above the industry average. Given its robust revenue growth of 38.50%, this premium appears sustainable.
What is the current P/B ratio for Guardant Health Inc (GH) as of Jan 09 2026?
As of Jan 09 2026, Guardant Health Inc (GH) has a P/B ratio of -35.88. This indicates that the market values GH at -35.88 times its book value.
What is the current FCF Yield for Guardant Health Inc (GH) as of Jan 09 2026?
As of Jan 09 2026, Guardant Health Inc (GH) has a FCF Yield of -2.00%. This means that for every dollar of Guardant Health Inc’s market capitalization, the company generates -2.00 cents in free cash flow.
What is the current Forward P/E ratio for Guardant Health Inc (GH) as of Jan 09 2026?
As of Jan 09 2026, Guardant Health Inc (GH) has a Forward P/E ratio of -62.53. This means the market is willing to pay $-62.53 for every dollar of Guardant Health Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Guardant Health Inc (GH) as of Jan 09 2026?
As of Jan 09 2026, Guardant Health Inc (GH) has a Forward P/S ratio of 11.32. This means the market is valuing GH at $11.32 for every dollar of expected revenue over the next 12 months.